Literature DB >> 10803840

CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group.

L F Barcellos1, A M Schito, J B Rimmler, E Vittinghoff, A Shih, R Lincoln, S Callier, M K Elkins, D E Goodkin, J L Haines, M A Pericak-Vance, S L Hauser, J R Oksenberg.   

Abstract

Multiple sclerosis (MS) is a common disease of the central nervous system characterized by myelin loss and progressive neurological dysfunction. An underlying genetic susceptibility plays a clear role in the etiology of MS, likely acting in concert with an undefined environmental exposure. Full-genome screenings in multiplex MS families have identified several susceptibility regions, supporting a polygenic model for MS. Among these regions, evidence for weak linkage was observed at 3p/3cen suggesting the presence of an MS gene(s) of modest effect. Encoded here are two chemokine receptors, CCR5 and CCR2B. We examined the chromosome 3p21-24 region in 125 MS families (322 total affecteds and 200 affected sib-pairs), and performed genetic analyses of CCR5 and CCR2B loci and two nearby markers (D3S1289 and D3S1300) using both linkage- and association-based tests. No evidence of linkage to MS was observed for any of the tested markers. Affected relative-pair (SimIBD) and sib-pair analyses (ASPEX), and association testing (sib-TDT) for each locus were also not significant. However, age of onset was approximately 3 years later in patients carrying the CCR5delta32 deletion (P=0.018 after controlling for gender effects). Thus, chemokine receptor expression may be associated with differential disease onset in a subset of patients, and may provide a therapeutic target to modulate inflammatory demyelination.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10803840     DOI: 10.1007/s002510050621

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  18 in total

1.  CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaques.

Authors:  Jessica E Taaffe; Steven E Bosinger; Gregory Q Del Prete; James G Else; Sarah Ratcliffe; Christopher D Ward; Thi Migone; Mirko Paiardini; Guido Silvestri
Journal:  J Med Primatol       Date:  2011-11-14       Impact factor: 0.667

Review 2.  [Chemokine--possible new options for the treatment of multiple sclerosis].

Authors:  C Trebst; R M Ransohoff; A Windhagen; M Stangel
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

3.  Transcriptional regulation of the chemokine co-receptor CCR5 by the cAMP/PKA/CREB pathway.

Authors:  Anupam Banerjee; Vanessa Pirrone; Brian Wigdahl; Michael R Nonnemacher
Journal:  Biomed Pharmacother       Date:  2011-05-30       Impact factor: 6.529

4.  Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta.

Authors:  Latt Latt Aung; Patricia Fitzgerald-Bocarsly; Suhayl Dhib-Jalbut; Konstantin Balashov
Journal:  J Neuroimmunol       Date:  2010-09-14       Impact factor: 3.478

5.  Variants of CCR5, which are permissive for HIV-1 infection, show distinct functional responses to CCL3, CCL4 and CCL5.

Authors:  H-F Dong; K Wigmore; M N Carrington; M Dean; J A Turpin; O M Z Howard
Journal:  Genes Immun       Date:  2005-10       Impact factor: 2.676

6.  CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis.

Authors:  C Trebst; T L Sørensen; P Kivisäkk; M K Cathcart; J Hesselgesser; R Horuk; F Sellebjerg; H Lassmann; R M Ransohoff
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

Review 7.  Dendritic cells as therapeutic targets in neuroinflammation.

Authors:  Felix Luessi; Frauke Zipp; Esther Witsch
Journal:  Cell Mol Life Sci       Date:  2016-03-12       Impact factor: 9.261

8.  HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course.

Authors:  L F Barcellos; J R Oksenberg; A B Begovich; E R Martin; S Schmidt; E Vittinghoff; D S Goodin; D Pelletier; R R Lincoln; P Bucher; A Swerdlin; M A Pericak-Vance; J L Haines; S L Hauser
Journal:  Am J Hum Genet       Date:  2003-01-28       Impact factor: 11.025

Review 9.  Role and therapeutic value of dendritic cells in central nervous system autoimmunity.

Authors:  F J Quintana; A Yeste; I D Mascanfroni
Journal:  Cell Death Differ       Date:  2014-08-29       Impact factor: 15.828

10.  CCR5-delta 32 allele is associated with the risk of developing multiple sclerosis in the Iranian population.

Authors:  Majid Shahbazi; Hamid Ebadi; Davood Fathi; Danial Roshandel; Mana Mahamadhoseeni; Azam Rashidbaghan; Narges Mahammadi; Mahammad Reza Mahammadi; Mahdi Zamani
Journal:  Cell Mol Neurobiol       Date:  2009-12       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.